Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research (Q38121519)

29 August 2017

Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research (English)

1 reference

29 August 2017

Chiara Fabbri

1

0 references

Alessandro Serretti

object named as

Alessandro Serretti

series ordinal

3

0 references

author name string

Giulia Di Girolamo

series ordinal

2

1 reference

29 August 2017

12 July 2013

1 reference

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

29 August 2017

1 reference

29 August 2017

162B

1 reference

29 August 2017

6

1 reference

29 August 2017

487-520

1 reference

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.

29 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The European Study of the Epidemiology of Mental Disorders (ESEMeD) project: an epidemiological basis for informing mental health policies in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Early response of rat brain tryptophan hydroxylase activity to cycloheximide, puromycin and corticosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Norepinephrine and serotonin transporter genes: impact on treatment response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Akt/GSK3 signaling in the action of psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Gene-gene interaction of glycogen synthase kinase 3-β and serotonin transporter on human antidepressant response to sleep deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Distinguishing true from false positives in genomic studies: p values

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Interaction between genetic polymorphisms and stressful life events in first episode depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Discriminative stimulus effects of centrally administered isoproterenol in rats: mediation by beta-1 adrenergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Characterization of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The role of dopamine in the mechanism of action of antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter gene polymorphisms and sertraline response in major depression patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Identification and functional characterization of three novel alleles for the serotonin transporter-linked polymorphic region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Clinical aspects of the MDR1 (ABCB1) gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

RNAi-mediated serotonin transporter suppression rapidly increases serotonergic neurotransmission and hippocampal neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Number of risk genotypes is a risk factor for major depressive disorder: a case control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A genomewide association study of citalopram response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

5-HTTLPR modulates antidepressant efficacy in depressed women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Allelic Variation of Human Serotonin Transporter Gene Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter polymorphism and bleeding time during SSRI therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Moderation of antidepressant response by the serotonin transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Does prior antidepressant treatment of major depression impact brain function during current treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A genome-wide association study of a sustained pattern of antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A psychoneuroimmunological review on cytokines involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pathway-based analysis of GWAS datasets: effective but caution required

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Gender differences in antidepressant drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Variation in GNB3 predicts response and adverse reactions to antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A previously undescribed intron and extensive 5' upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic variants in FKBP5 affecting response to antidepressant drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: lack of association with clinical phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Depression: an inflammatory illness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Quantitative pharmacogenetics of nortriptyline: a novel approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

GSK3B polymorphisms alter transcription and splicing in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genome-wide association studies of antidepressant outcome: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic markers of suicidal ideation emerging during citalopram treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Functional genomics approaches in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Sequence-based CYP2D6 genotyping in the Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effects of triiodothyronine and fluoxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: regional differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Improving power of genome-wide association studies with weighted false discovery rate control and prioritized subset analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

No gene is an island: the flip-flop phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

HTR2A gene variation is involved in antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Prevention of stress-induced morphological and cognitive consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

SLC6A4 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter genotype and function in relation to antidepressant response in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A novel 5-HT(2A) receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Investigation of serotonin-related genes in antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Population genetic study of the brain-derived neurotrophic factor (BDNF) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Chaperoning of glucocorticoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The association between serotonin 2C receptor polymorphisms and weight gain and eating behavior in patients using mirtazapine: a prospective follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The Human Phosphatidylinositol Phosphatase SAC1 Interacts with the Coatomer I Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic variation in microRNA networks: the implications for cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A functional polymorphism in the monoamine oxidase A gene promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

SSRIs antidepressant activity is influenced by G beta 3 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter gene variants and behavior: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Beware of risk for increased false positive rates in genome-wide association studies for phenotypic variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Monoamine oxidase: from genes to behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Differential serotonin transport is linked to the rh5-HTTLPR in peripheral blood cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Serotonin transporter gene and response to lithium augmentation in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Contribution of common genetic variants to antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Antidepressant response and the serotonin transporter gene-linked polymorphic region

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

BDNF Val66Met genotype and 6-month remission rates in late-life depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genome-wide association scan of trait depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

MAOA gene polymorphisms and response to mirtazapine in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genes, environment, and individual differences in responding to treatment for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pharmacogenetic perspectives gained from twin and family studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Dopaminergic mechanism of antidepressant action in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

GCTA: a tool for genome-wide complex trait analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Use of cell lines in the investigation of pharmacogenetic loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Regional mRNA expression of a second tryptophan hydroxylase isoform in postmortem tissue samples of two human brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

DNA sequence variants of the FKBP5 gene are associated with unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FAJMG.B.32184

21 January 2018

Identifiers

DOI

10.1002/AJMG.B.32184

1 reference

29 August 2017

1 reference

PubMed ID

23852853